Zanubrutinib Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
The Magnolia Trial: Zanubrutinib, A Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma
Clin. Cancer Res 2021 Sep 15;na(na)na, S Opat, A Tedeschi, K Linton, P McKay, B Hu, H Chan, J Jin, M Sobieraj-Teague, PL Zinzani, M Coleman, C Thieblemont, P Browett, X Ke, M Sun, R Marcus, CA Portell, K Ardeshna, F Bijou, P Walker, EA Hawkes, S Mapp, SJ Ho, D Talaulikar, KS Zhou, M Co, X Li, W Zhou, M Cappellini, C Tankersley, J Huang, J TrotmanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.